Glu-ureido-based inhibitors of prostate-specific membrane antigen: Lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers

Journal of Nuclear Medicine

Volumn 58, Issue , 2017, Pages 17S-26S

  Kopka, Klaus ^a   Benešová, Martina ^b,c   Bařinka, Cyril ^d   Haberkorn, Uwe ^a,e   Babich, John ^f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b ETH ZURICH   (Switzerland)

^c ETH Zurich   (Switzerland)

^d Institute of Biotechnology CAS   (Czech Republic)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Prostate cancer; PSMA radiotracers; Radioligand therapy; Small molecule PSMA inhibitors; Theranostic PSMA radioligands

Indexed keywords

GALLIUM 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITOR; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; UREA;

DRUG TARGETING; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION; THERANOSTIC NANOMEDICINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIAGNOSIS; DRUG DEVELOPMENT; MOLECULAR WEIGHT; PROCEDURES;

ANIMALS; ANTIGENS, SURFACE; DIAGNOSIS; DRUG DISCOVERY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MOLECULAR WEIGHT; RADIOACTIVE TRACERS; UREA;

EID: 85028804735     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.186775     Document Type: Review

References (97)

1. Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241-268.
2. Pillai MR, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016;43:692-720.
3. Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9-15.
4. Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46: 405-418.
5. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamateurea- lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69: 6932-6940.
6. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347-357.
7. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
8. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga] gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39: 1085-1086.
9. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298-301.
10. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004;47:1729-1738.
11. Jackson PF, Cole DC, Slusher BS, et al. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem. 1996;39:619-622.
12. Jackson PF, Slusher BS. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem. 2001;8:949-957.
13. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028.
14. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-1451.
15. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
16. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
17. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
18. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
19. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 highaffinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
20. Benešová M, Bauder-Wüst U, Schäfer M, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59:1761-1775.
21. Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914-920.
22. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proofof- concept human studies. J Nucl Med. 2015;56:1169-1176.
23. Rauscher I, Maurer T, Souvatzoglou M, et al. Intrapatient comparison of 111In- PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer. Clin Nucl Med. 2016;41:e397-e402.
24. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85-90.
25. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMAtargeted a-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941-1944.
26. Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for 177Lu-DKFZ-PSMA- 617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42-51.
27. Yadav MP, Ballal S, Tripathi M, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81-91.
28. Cardinale J, Schäfer M, Benešová M, et al. Preclinical evaluation of 18FPSMA- 1007: a new PSMA ligand for prostate cancer imaging. J Nucl Med. 2017;58:425-431.
29. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678-688.
30. Giesel FL, Kesch C, Yun M, et al. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer. December 29, 2016 [Epub ahead of print].
31. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1, 3-dicarboxypropyl]carbamoyl]- 4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
32. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003-1010.
33. Rowe SP, Macura KJ, Ciarallo A, et al. Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer. J Nucl Med. 2016;57:46-53.
34. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoropyridine- 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-7653.
35. Rowe SP, Macura KJ, Mena E, et al. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411-419.
36. Vallabhajosula S, Nikolopoulou A, Babich JW, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791-1798.
37. Osborne J, Akhtar NH, Vallabhajosula S, et al. Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): new molecular imaging probes to detect metastatic prostate adenocarcinoma (PC) [abstract]. J Clin Oncol. 2012;30(suppl 5):173.
38. Robu S, Schottelius M, Eiber M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235-242.
39. Umbricht CA, Benešová M, Schmid RM, et al. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617: preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 2017;7:9.
40. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
41. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostatespecific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA. 2005;102:5981-5986.
42. Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006;25:1375-1384.
43. Pavlícek J, Ptácek J, Barinka C. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme. Curr Med Chem. 2012;19:1300-1309.
44. Pavlicek J, Ptacek J, Cerny J, et al. Structural characterization of P19-diversified urea-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2014;24:2340-2345.
45. Wang H, Byun Y, Barinka C, et al. Bioisosterism of urea-based GCPII inhibitors: synthesis and structure-activity relationship studies. Bioorg Med Chem Lett. 2010;20:392-397.
46. Plechanovová A, Byun Y, Alquicer G, et al. Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem. 2011;54:7535-7546.
47. Ganguly T, Dannoon S, Hopkins MR, et al. A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015;42:780-787.
48. Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51:7737-7743.
49. Barinka C, Rovenská M, Mlcochová P, et al. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem. 2007; 50:3267-3273.
50. Novakova Z, Cerny J, Choy CJ, et al. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J. 2016;283:130-143.
51. Dannoon S, Ganguly T, Cahaya H, et al. Structure-activity relationship of 18Flabeled phosphoramidate peptidomimetic prostate-specific membrane antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. J Med Chem. 2016;59:5684-5694.
52. Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711-12716.
53. Tykvart J, Schimer J, Jancarik A, et al. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem. 2015;58:4357-4363.
54. Tykvart J, Schimer J, Barinkova J, et al. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. Bioorg Med Chem. 2014;22:4099-4108.
55. Youn S, Kim KI, Ptacek J, et al. Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: synthesis and structural characterization. Bioorg Med Chem Lett. 2015;25:5232-5236.
56. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809-1818.
57. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846.
58. Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40:209-218.
59. Aloj L, Aurilio M, Rinaldi V, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COSTAction BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1417-1425.
60. Roosenburg S, Laverman P, Joosten L, et al. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with 64Cu, 68Ga, and 111In. Mol Pharm. 2014;11:3930-3937.
61. Minamimoto R, Hancock S, Schneider B, et al. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57:557-562.
62. Zhang J, Li D, Lang L, et al. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in healthy volunteers and glioma patients. J Nucl Med. 2016;57:9-14.
63. Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga- NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57:715-720.
64. Vag T, Gerngross C, Herhaus P, et al. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57:741-746.
65. Herrmann K, Schottelius M, Lapa C, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57:248-251.
66. Bluemel C, Hahner S, Heinze B, et al. Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients. Clin Nucl Med. 2017;42:e29-e34.
67. Kratochwil C, Giesel FL, López-Benítez R, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16:2899-2905.
68. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga- DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
69. Breeman WA, de Blois E, Sze Chan H, et al. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314-321.
70. Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptortargeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106-2119.
71. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920.
72. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
73. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252.
74. Fani M, Peitl PK, Velikyan I. Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms. Pharmaceuticals (Basel). 2017;10:30.
75. Murphy GP, Su S, Jarisch J, Kenny GM. Serum levels of PSMA. Prostate. 2000;42:318-319.
76. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
77. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
78. Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem. 1999;274:8470-8483.
79. O'Keefe DS, Bacich DJ, Heston WDW. Comparative analysis of prostatespecific membrane antigen (PSMA) versus a prostate-specific membrane antigen- like gene. Prostate. 2004;58:200-210.
80. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate- specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552-558.
81. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43:150-157.
82. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated a-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998;286:1020-1025.
83. Evans JC, Malhotra M, Cryan JF, O'Driscoll CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol. 2016;173:3041-3079.
84. Wright GL Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
85. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
86. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-172.
87. Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017-2024.
88. Gerlinger M, Rowan AJ, Horswell A, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
89. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumoral heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012;4:127ps10.
90. Mitchell T, Neal DE. The genomic evolution of human prostate cancer. Br J Cancer. 2015;113:193-198.
91. Murphy TM, Severns V, Brown DC, et al. Prostate cancer targeting motifs: expression of avb3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate. 2011;71:1-17.
92. Ananias HJ, van der Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate- specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101-1108.
93. Afshar-Oromieh A, Hetzheim H, Kübler W, et al. Radiation dosimetry of 68Ga- PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611-1620.
94. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA- 617. J Nucl Med. 2016;57:1170-1176.
95. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855-861.
96. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostatespecific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565-574.
97. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostatespecific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.